Epigenome-based personalized medicine in human cancer

Epigenomics

Volumn 8, Issue 1, 2016, Pages 119-133

  Yan, Wenji ^a   Herman, James G ^b   Guo, Mingzhou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

DNA methylation; epigenome; histone modification; personalized medicine; targeted therapy

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZACITIDINE; BROMODOMAIN INHIBITOR; DECITABINE; DOT1L INHIBITOR; EZH2 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; TAZEMETOSTAT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CHEMOSENSITIVITY; DNA METHYLATION; EPIGENETICS; GENE; GENE MUTATION; GLIOMA; HUMAN; LUNG CANCER; MARKER GENE; MGMT GENE; MYELODYSPLASTIC SYNDROME; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DNA SEQUENCE; DRUG EFFECTS; DRUG POTENTIATION; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG SYNERGISM; EPIGENESIS, GENETIC; GENOME, HUMAN; HISTONE DEACETYLASE INHIBITORS; HUMANS; NEOPLASMS; PRECISION MEDICINE; SEQUENCE ANALYSIS, DNA;

EID: 84954520555     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.15.84     Document Type: Review

References (160)

1. Guo M, Ren J, Brock MV, Herman JG, Carraway HE. Promoter methylation of HIN-1 in the progression to esophageal squamous cancer. Epigenetics 3(6), 336-341 (2008).
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
3. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 12(15), 4515-4522 (2006).
4. Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours-lessons from the past. Nat. Rev. Clin. Oncol. 10(5), 256-266 (2013).
5. Hamburg MA, Collins FS. The path to personalized medicine. N. Engl. J. Med. 363(4), 301-304 (2010).
6. Collins FS, Varmus H. A new initiative on precision medicine. N. Engl. J. Med. 372(9), 793-795 (2015).
7. Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N. Engl. J. Med. 366(6), 489-491 (2012).
8. Katsnelson A. Momentum grows to make 'personalized' medicine more 'precise'. Nat. Med. 19(3), 249 (2013).
9. Dolsten M, Sogaard M. Precision medicine: an approach to R&D for delivering superior medicines to patients. Clin. Transl. Med. 1(1), 7 (2012).
10. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
11. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW. Cancer genome landscapes. Science 339(6127), 1546-1558 (2013).
12. Beggs AD, Jones A, El-Bahrawy M, Abulafi M, Hodgson SV, Tomlinson IP. Whole-genome methylation analysis of benign and malignant colorectal tumours. J. Pathol. 229(5), 697-704 (2013).
13. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA 99(6), 3740-3745 (2002).
14. Stirzaker C, Taberlay PC, Statham AL, Clark SJ. Mining cancer methylomes: prospects and challenges. Trends Genet. 30(2), 75-84 (2014).
15. Jeong M, Goodell MA. New answers to old questions from genome-wide maps of DNA methylation in hematopoietic cells. Exp. Hematol. 42(8), 609-617 (2014).
16. Jeschke J, Collignon E, Fuks F. DNA methylome profiling beyond promoters-taking an epigenetic snapshot of the breast tumor microenvironment. FEBS J. 282(9), 1801-1814 (2015).
17. Irizarry RA, Ladd-Acosta C, Wen B et al. The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
18. Doi A, Park IH, Wen B et al. Differential methylation of tissue-and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12), 1350-1353 (2009).
19. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat. Rev. Cancer 4(4), 296-307 (2004).
20. Esteller M, Garcia-Foncillas J, Andion E et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343(19), 1350-1354 (2000).
21. Scolnick DM, Halazonetis TD. Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406(6794), 430-435 (2000).
22. Yun T, Liu Y, Gao D et al. Methylation of CHFR sensitizes esophageal squamous cell cancer to docetaxel and paclitaxel. Genes Cancer 6(1-2), 38-48 (2015).
23. Derks S, Cleven AH, Melotte V et al. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. 33(1), 161-171 (2014).
24. Li Y, Yang Y, Lu Y et al. Predictive value of CHFR and MLH1 methylation in human gastric cancer. Gastric Cancer 18(2), 280-287 (2015).
25. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat. Med. 9(5), 568-574 (2003).
26. Swisher EM, Gonzalez RM, Taniguchi T et al. Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas. Mol. Cancer 8, 48 (2009).
27. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat. Rev. Genet. 13(10), 679-692 (2012).
28. Tanaka M, Chang P, Li Y et al. Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. Clin. Cancer Res. 17(13), 4531-4540 (2011).
29. Veeck J, Ropero S, Setien F et al. BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J. Clin. Oncol. 28(29), e563-e564 (2010).
30. Strathdee G, Mackean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18(14), 2335-2341 (1999).
31. Dejeux E, Ronneberg JA, Solvang H et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 9, 68 (2010).
32. Lee JH, Kang MJ, Han HY et al. Epigenetic alteration of PRKCDBP in colorectal cancers and its implication in tumor cell resistance to TNF-induced apoptosis. Clin. Cancer Res. 17(24), 7551-7562 (2011).
33. Ramirez JL, Rosell R, Taron M et al. 14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group. J. Clin. Oncol. 23(36), 9105-9112 (2005).
34. Ebert MP, Tanzer M, Balluff B et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer. N. Engl. J. Med. 366(1), 44-53 (2012).
35. Chekhun VF, Kulik GI, Yurchenko OV et al. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett. 231(1), 87-93 (2006).
36. Soengas MS, Capodieci P, Polsky D et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409(6817), 207-211 (2001).
37. Iorns E, Turner NC, Elliott R et al. Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer. Cancer Cell 13(2), 91-104 (2008).
38. Ibanez De Caceres I, Cortes-Sempere M, Moratilla C et al. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer. Oncogene 29(11), 1681-1690 (2010).
39. Faller WJ, Rafferty M, Hegarty S et al. Metallothionein 1E is methylated in malignant melanoma and increases sensitivity to cisplatin-induced apoptosis. Melanoma Res. 20(5), 392-400 (2010).
40. Ai L, Kim WJ, Demircan B et al. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis 29(3), 510-518 (2008).
41. Shen L, Kondo Y, Ahmed S et al. Drug sensitivity prediction by CpG island methylation profile in the NCI-60 cancer cell line panel. Cancer Res. 67(23), 11335-11343 (2007).
42. Kim H, Park J, Jung Y et al. DNA methyltransferase 3-like affects promoter methylation of thymine DNA glycosylase independently of DNMT1 and DNMT3B in cancer cells. Int. J. Oncol. 36(6), 1563-1572 (2010).
43. Ahuja N, Easwaran H, Baylin SB. Harnessing the potential of epigenetic therapy to target solid tumors. J. Clin. Invest. 124(1), 56-63 (2014).
44. Sekeres MA, Tiu RV, Komrokji R et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 120(25), 4945-4951 (2012).
45. Aparicio A, Weber JS. Review of the clinical experience with 5-azacytidine and 5-aza-2-deoxycytidine in solid tumors. Curr. Opin. Invest. Drugs 3(4), 627-633 (2002).
46. Tsai HC, Li H, Van Neste L et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21(3), 430-446 (2012).
47. Marquez VE, Barchi JJ Jr, Kelley JA et al. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy. The magic of its chemistry and biology. Nucleosides, Nucleotides Nucleic Acids 24(5-7), 305-318 (2005).
48. Cheng JC, Weisenberger DJ, Gonzales FA et al. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells. Mol. Cell. Biol. 24(3), 1270-1278 (2004).
49. Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol. Oncol. doi:10.1016/j. molonc.2015.06.002 (2015) (Epub ahead of print).
50. Laille E, Savona MR, Scott BL, Boyd TE, Dong Q, Skikne B. Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. J. Clin. Pharmacol. 54(6), 630-639 (2014).
51. Ren J, Singh BN, Huang Q et al. DNA hypermethylation as a chemotherapy target. Cell. Signal. 23(7), 1082-1093 (2011).
52. Tsai HC, Baylin SB. Cancer epigenetics: linking basic biology to clinical medicine. Cell Res. 21(3), 502-517 (2011).
53. Bachman KE, Rountree MR, Baylin SB. DNMT3A and DNMT3B are transcriptional repressors that exhibit unique localization properties to heterochromatin. J. Biol. Chem. 276(34), 32282-32287 (2001).
54. Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25(3), 338-342 (2000).
55. Zhou VW, Goren A, Bernstein BE. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 12(1), 7-18 (2011).
56. Visel A, Blow MJ, Li Z et al. ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature 457(7231), 854-858 (2009).
57. Kornblihtt AR, Schor IE, Allo M, Blencowe BJ. When chromatin meets splicing. Nat. Struct. Mol. Biol. 16(9), 902-903 (2009).
58. Luco RF, Pan Q, Tominaga K, Blencowe BJ, Pereira-Smith OM, Misteli T. Regulation of alternative splicing by histone modifications. Science 327(5968), 996-1000 (2010).
59. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin Cancer Cell 22(1), 9-20 (2012).
60. Guo M, Yan W. Epigenetics of gastric cancer. Methods Mol. Biol. 1238, 783-799 (2015).
61. Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR, Smith MA. Epigenetic mechanisms in gastric cancer. Epigenomics 4(3), 279-294 (2012).
62. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).
63. Yan W, Guo M. Epigenetics of colorectal cancer. Methods Mol. Biol. 1238, 405-424 (2015).
64. Lee HZ, Kwitkowski VE, Del Valle PL et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin. Cancer Res. 21(12), 2666-2670 (2015).
65. De Souza C, Chatterji BP. HDAC inhibitors as novel anticancer therapeutics. Recent Pat. Anticancer Drug Discov. 10(2), 145-162 (2015).
66. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat. Biotechnol. 28(10), 1069-1078 (2010).
67. Balasubramanian S, Ramos J, Luo W, Sirisawad M, Verner E, Buggy JJ. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia 22(5), 1026-1034 (2008).
68. Daigle SR, Olhava EJ, Therkelsen CA et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20(1), 53-65 (2011).
69. Wee S, Dhanak D, Li H et al. Targeting epigenetic regulators for cancer therapy. Ann. NY Acad. Sci. 1309, 30-36 (2014).
70. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21(9), 1050-1063 (2007).
71. EU Clinical Trials Register. www.clinicaltrialsregister.eu
72. Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma. https://clinicaltrials.gov/ct2/show/NCT02034123
73. Lucas X, Gunther S. Targeting the BET family for the treatment of leukemia. Epigenomics 6(2), 153-155 (2014).
74. Dawson MA, Prinjha RK, Dittmann A et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478(7370), 529-533 (2011).
75. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6), 904-917 (2011).
76. Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 6(11), 838-849 (2005).
77. Tsukada Y, Fang J, Erdjument-Bromage H et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439(7078), 811-816 (2006).
78. Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone methylations in the human genome. Cell 129(4), 823-837 (2007).
79. Hancock RL, Dunne K, Walport LJ, Flashman E, Kawamura A. Epigenetic regulation by histone demethylases in hypoxia. Epigenomics doi:10.2217/epi.15.24 (2015) (Epub ahead of print).
80. Lall S. Primers on chromatin. Nat. Struct. Mol. Biol. 14(11), 1110-1115 (2007).
81. Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol. Cell 48(4), 491-507 (2012).
82. Takawa M, Masuda K, Kunizaki M et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102(7), 1298-1305 (2011).
83. Kondo Y. Targeting histone methyltransferase EZH2 as cancer treatment. J. Biochem. 156(5), 249-257 (2014).
84. Tan JZ, Yan Y, Wang XX, Jiang Y, Xu HE. EZH2: biology, disease, and structure-based drug discovery. Acta Pharmacol. Sin. 35(2), 161-174 (2014).
85. Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647(1-2), 21-29 (2008).
86. Copeland RA, Solomon ME, Richon VM. Protein methyltransferases as a target class for drug discovery. Nat. Rev. Drug Discov. 8(9), 724-732 (2009).
87. Knutson SK, Wigle TJ, Warholic NM et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat. Chem. Biol. 8(11), 890-896 (2012).
88. Mccabe MT, Ott HM, Ganji G et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427), 108-112 (2012).
89. Knutson SK, Kawano S, Minoshima Y et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol. Cancer Ther. 13(4), 842-854 (2014).
90. Deb G, Singh AK, Gupta S. EZH2: not EZHY (easy) to deal. Mol. Cancer Res. 12(5), 639-653 (2014).
91. Nguyen AT, Zhang Y. The diverse functions of DOT1 and H3K79 methylation. Genes Dev. 25(13), 1345-1358 (2011).
92. Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol. Med. 10(10), 500-507 (2004).
93. Daigle SR, Olhava EJ, Therkelsen CA et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122(6), 1017-1025 (2013).
94. Bitoun E, Oliver PL, Davies KE. The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. Hum. Mol. Genet. 16(1), 92-106 (2007).
95. Biswas D, Milne TA, Basrur V et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc. Natl Acad. Sci. USA 108(38), 15751-15756 (2011).
96. Mueller D, Bach C, Zeisig D et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 110(13), 4445-4454 (2007).
97. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol. 7(11), e1000249 (2009).
98. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 17(2), 198-212 (2010).
99. Park G, Gong Z, Chen J, Kim JE. Characterization of the DOT1L network: implications of diverse roles for DOT1L. Protein J. 29(3), 213-223 (2010).
100. Zhang W, Xia X, Reisenauer MR, Hemenway CS, Kone BC. DOT1A-AF9 complex mediates histone H3 Lys-79 hypermethylation and repression of ENaCalpha in an aldosterone-sensitive manner. J. Biol. Chem. 281(26), 18059-18068 (2006).
101. Mohan M, Herz HM, Takahashi YH et al. Linking H3K79 trimethylation to Wnt signaling through a novel DOT1-containing complex (DotCom). Genes Dev. 24(6), 574-589 (2010).
102. Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood 117(25), 6912-6922 (2011).
103. Monroe SC, Jo SY, Sanders DS et al. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp. Hematol. 39(1), 77-86 e71-75 (2011).
104. Milne TA, Martin ME, Brock HW, Slany RK, Hess JL. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications. Cancer Res. 65(24), 11367-11374 (2005).
105. Kim W, Kim R, Park G, Park JW, Kim JE. Deficiency of H3K79 histone methyltransferase DOT-like protein (DOT1L) inhibits cell proliferation. J. Biol. Chem. 287(8), 5588-5599 (2012).
106. Zhang L, Deng L, Chen F et al. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer. Oncotarget 5(21), 10665-10677 (2014).
107. Stein EM, Tallman MS. Mixed lineage rearranged leukaemia: pathogenesis and targeting DOT1L. Curr. Opin. Hematol. 22(2), 92-96 (2015).
108. Yu W, Chory EJ, Wernimont AK et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nat. Commun. 3, 1288 (2012).
109. Basavapathruni A, Jin L, Daigle SR et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem. Biol. Drug Des. 80(6), 971-980 (2012).
110. Shi Y, Lan F, Matson C et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119(7), 941-953 (2004).
111. You A, Tong JK, Grozinger CM, Schreiber SL. CoREST is an integral component of the CoREST-human histone deacetylase complex. Proc. Natl Acad. Sci. USA 98(4), 1454-1458 (2001).
112. Hou H, Yu H. Structural insights into histone lysine demethylation. Curr. Opin. Struct. Biol. 20(6), 739-748 (2010).
113. Wang Y, Zhang H, Chen Y et al. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 138(4), 660-672 (2009).
114. Metzger E, Wissmann M, Yin N et al. LSD1 demethylates repressive histone marks to promote androgen-receptordependent transcription. Nature 437(7057), 436-439 (2005).
115. Kahl P, Gullotti L, Heukamp LC et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66(23), 11341-11347 (2006).
116. Hayami S, Kelly JD, Cho HS et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128(3), 574-586 (2011).
117. Kauffman EC, Robinson BD, Downes MJ et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 50(12), 931-944 (2011).
118. Schulte JH, Lim S, Schramm A et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 69(5), 2065-2071 (2009).
119. Lee MG, Wynder C, Schmidt DM, McCafferty DG, Shiekhattar R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13(6), 563-567 (2006).
120. Etani T, Suzuki T, Naiki T et al. NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect. Oncotarget 6(5), 2865-2878 (2015).
121. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat. Rev. Genet. 7(9), 715-727 (2006).
122. Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy. Nat. Rev. Drug Discov. 12(12), 917-930 (2013).
123. Berry WL, Janknecht R. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 73(10), 2936-2942 (2013).
124. Cloos PA, Christensen J, Agger K et al. The putative oncogene GASC1 demethylates tri-and dimethylated lysine 9 on histone H3. Nature 442(7100), 307-311 (2006).
125. Ntziachristos P, Tsirigos A, Welstead GG et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514(7523), 513-517 (2014).
126. Lohse B, Nielsen AL, Kristensen JB et al. Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors. Angew. Chem. Int. Ed. Engl. 50(39), 9100-9103 (2011).
127. Wang L, Chang J, Varghese D et al. A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth. Nat. Commun. 4, 2035 (2013).
128. King ON, Li XS, Sakurai M et al. Quantitative highthroughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE 5(11), e15535 (2010).
129. Chang KH, King ON, Tumber A et al. Inhibition of histone demethylases by 4-carboxy-2,2-bipyridyl compounds. ChemMedChem 6(5), 759-764 (2011).
130. Schiller R, Scozzafava G, Tumber A et al. A cell-permeable ester derivative of the JmjC histone demethylase inhibitor IOX1. ChemMedChem 9(3), 566-571 (2014).
131. Steller P. [Radiographic diagnosis of sliding hiatal hernias in children]. Bratisl. Lek. Listy 54(2), 224-229 (1970).
132. Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov. 13(5), 337-356 (2014).
133. Barbieri I, Cannizzaro E, Dawson MA. Bromodomains as therapeutic targets in cancer. Brief. Funct. Genom. 12(3), 219-230 (2013).
134. Bayarsaihan D, Shin DG. Epigenetic drug therapy based on bromodomain inhibition. Epigenomics 6(5), 473-476 (2014).
135. Chaidos A, Caputo V, Karadimitris A. Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Ther. Adv. Hematol. 6(3), 128-141 (2015).
136. Papavassiliou KA, Papavassiliou AG. Bromodomains: pockets with therapeutic potential. Trends Mol. Med. 20(9), 477-478 (2014).
137. Filippakopoulos P, Qi J, Picaud S et al. Selective inhibition of BET bromodomains. Nature 468(7327), 1067-1073 (2010).
138. Chung CW, Coste H, White JH et al. Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54(11), 3827-3838 (2011).
139. Zeng L, Li J, Muller M et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 127(8), 2376-2377 (2005).
140. Braiteh F, Soriano AO, Garcia-Manero G et al. Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14(19), 6296-6301 (2008).
141. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60(21), 6039-6044 (2000).
142. Juergens RA, Wrangle J, Vendetti FP et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1(7), 598-607 (2011).
143. Walter RB, Medeiros BC, Gardner KM et al. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a Phase I/II study. Haematologica 99(1), 54-59 (2014).
144. Singh MM, Johnson B, Venkatarayan A et al. Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol. doi:10.1093/neuonc/nov041 (2015) (Epub ahead of print).
145. Fillmore CM, Xu C, Desai PT et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520(7546), 239-242 (2015).
146. Klaus CR, Iwanowicz D, Johnston D et al. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells. J. Pharmacol. Exp. Ther. 350(3), 646-656 (2014).
147. Garofalo M, Leva GD, Croce CM. MicroRNAs as anticancer therapy. Curr. Pharm. Des. 20(33), 5328-5335 (2014).
148. Ji Q, Hao X, Meng Y et al. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. BMC Cancer 8, 266 (2008).
149. Meng W, Jiang L, Lu L et al. Anti-miR-155 oligonucleotide enhances chemosensitivity of U251 cell to taxol by inducing apoptosis. Cell Biol. Int. 36(7), 653-659 (2012).
150. Garzon R, Marcucci G, Croce CM. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 9(10), 775-789 (2010).
151. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther. 18(12), 1121-1126 (2011).
152. Wu Y, Crawford M, Mao Y et al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer. Molecular therapy. Nucleic Acids 2, e84 (2013).
153. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease Gene Ther. 13(6), 496-502 (2006).
154. Krichevsky AM, Gabriely G. miR-21: a small multi-faceted RNA. J. Cell. Mol. Med. 13(1), 39-53 (2009).
155. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 4(9), 721-726 (2007).
156. Li C, Feng Y, Coukos G, Zhang L. Therapeutic microRNA strategies in human cancer. AAPS J. 11(4), 747-757 (2009).
157. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod. Pathol. 26(2), 155-165 (2013).
158. Faghihi MA, Kocerha J, Modarresi F et al. RNAi screen indicates widespread biological function for human natural antisense transcripts. PLoS ONE doi: 10.1371/journal. pone.0013177 (2010) (Epub ahead of print).
159. Modarresi F, Faghihi MA, Lopez-Toledano MA et al. Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. Nat. Biotechnol. 30(5), 453-459 (2012).
160. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293 (2010).